Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Efforts to Improve Quality of Migraine CareRelease Date:Partner: The Japanese Headache SocietyQuality Improvement Internal Medicine Japan Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool (Decision Aid)Release Date:Research Rare Disease USA 2026 Hemophilia Fellowship – United StatesRelease Date:Fellowship Rare Disease All Improving Precision Oncology Care Through Molecular Diagnostic Integration and Data Quality ImprovementRelease Date:Quality Improvement Oncology Kazakhstan Implementing Germline and Somatic Testing for Precision Medicine in Community-Based Prostate Cancer CareEducation Oncology USA Improving Shared Decision Making in Hemophilia: Visiting Professorship ProgramRelease Date:Partner: Hemostasis & Thrombosis Research Society (HTRS)Education Rare Disease USA Improving Metastatic Prostate Cancer (mPCa) Care Through Innovative StrategiesRelease Date:Quality Improvement Oncology All Novel Therapies for Relapsed/Refractory Large B-Cell Lymphoma in Community Oncology PracticeRelease Date:Education Oncology USA Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology China, France, Germany, Italy, Japan, Spain, Turkey, United Kingdom Pre-clinical Investigation of anti-TFPI-mediated Rebalancing Mechanisms in Non-Hemophilic Bleeding DisordersRelease Date:Research Rare Disease All Title Grant Type Focus Area Country Application Due Date Collaborative Community Oncology Support for Therapy Management in Relapsed/Refractory Multiple Myeloma (RRMM)Release Date:Education Oncology Italy, Japan, Spain, United Kingdom Emerging Data and Unmet Needs in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)Release Date:Education Oncology All New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer (mCRPC)Release Date:Education Oncology All Education in the Era of Emerging Hemophilia Therapy (Round 2)Release Date:Education Rare Disease USA Improving Actionable Biomarker Testing Through Technology-Enabled SolutionsRelease Date:Partner: Conquer Cancer, The ASCO FoundationQuality Improvement Oncology USA USP <797> Pharmaceutical Compounding-Sterile Preparations: Challenges and Special ConsiderationsRelease Date:Education Inflammation & Immunology USA Improving Shared Decision Making in Hemophilia: Visiting Professorship ProgramRelease Date:Partner: Hemostasis & Thrombosis Research Society (HTRS)Education Rare Disease USA Pharmacokinetics-Pharmacodynamics (PK-PD) Profile, Effectiveness and Safety of ATM-AVI in Special PopulationsRelease Date:Research Inflammation & Immunology China Unmet Need and Emerging Data in Muscle Invasive Bladder Cancer (MIBC)Education Oncology USA Bridging the Inflammatory Dermatosis Care Divide with TeledermatologyRelease Date:Partner: The George Washington UniversityQuality Improvement Inflammation & Immunology USA Impact of Rapid Diagnostic Tests (RDTs) on Treatment Pattern and Outcomes in Patients with Carbapenem-Resistant (CR) PathogensRelease Date:Research Inflammation & Immunology China Global Request for Proposals – Pfizer Clostridioides difficile (C. difficile) Research CollaborationRelease Date:Call for Collaborator(s) Vaccines France, Germany